Thus, studies on differences in the modulation of the amyloid and tau protein gene may provide key functional elements of the molecular landscape during neurodegeneration of CA1 and CA3 in the brain after cerebral ischemia and Alzheimer’s disease. This evidence concerns the gene MAPT and Alzheimer disease.